BioKangtai(SZ:300601) Xin Lang Cai Jing·2025-08-28 07:21Company Overview - Kangtai Biological Products Co., Ltd. is located in Nanshan District, Shenzhen, Guangdong Province, and was established on September 8, 1992. The company went public on February 7, 2017. Its main business involves the research, production, and sales of human vaccines [1]. - The revenue composition of Kangtai Biological is as follows: non-immunization program vaccines account for 93.70%, immunization program vaccines 3.71%, and others 2.59% [1]. Stock Performance - As of August 28, Kangtai Biological's stock price was 18.89 CNY per share, with a trading volume of 497 million CNY and a turnover rate of 2.96%. The total market capitalization is 21.099 billion CNY [1]. - The stock has experienced a decline for three consecutive days, with a cumulative drop of 5.55% during this period [1]. Shareholder Insights - Among the top ten circulating shareholders of Kangtai Biological, a fund under Yinhua Fund has reduced its holdings by 2.1063 million shares in the second quarter, now holding 6.2899 million shares, which represents 0.7% of the circulating shares. The estimated floating loss today is approximately 125,800 CNY, with a total floating loss of 6.9818 million CNY during the three-day decline [2]. - The fund, named Innovation Medicine (159992), was established on March 20, 2020, and has a current scale of 9.473 billion CNY. Year-to-date returns are 33.3%, ranking 738 out of 4222 in its category, while the one-year return is 53.07%, ranking 1544 out of 3776. Since its inception, it has incurred a loss of 7.19% [2]. Fund Management - The fund manager for Innovation Medicine is Ma Jun, who has a tenure of 12 years and 362 days, managing assets totaling 33.316 billion CNY. The best fund return during his tenure is 144.61%, while the worst is -75.58% [3]. - Another fund manager, Wang Shuai, has a tenure of 6 years and 64 days, managing assets of 20.936 billion CNY. His best fund return is 76.27%, and the worst is -32.36% [3].